Evaluation of In Vitro Activity of Ceftolozane/Tazobactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Pseudomonas aeruginosa Strains and Mechanisms of Carbapenem Resistance: Data from Tertiary Care Hospital

被引:2
|
作者
Hazirolan, Gulsen [1 ]
Ozkul, Ceren [2 ]
机构
[1] Hacettepe Univ, Dept Med Microbiol, Med Fac, Ankara, Turkiye
[2] Hacettepe Univ, Dept Pharmaceut Microbiol, Fac Pharm, Ankara, Turkiye
关键词
Carbapenems; Efflux Pumps; Pa beta N; Pseudomonas aeruginosa; Ceftolozane/Tazobactam; Ceftazidime/Avibactam; METALLO-BETA-LACTAMASE; MULTIPLEX PCR; EFFLUX PUMP; 1ST REPORT; AVIBACTAM; TAZOBACTAM; PREVALENCE; EXPRESSION; EMERGENCE;
D O I
10.5812/jjm-134090
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Carbapenem-resistant Pseudomonas aeruginosa is an endemic problem in several countries, notably Turkey. Objectives: This study aimed to investigate the underlying mechanisms contributing to the carbapenem resistance phenotype and enhance the in-vitro activity of ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (C/A) against carbapenem-resistant P. aeruginosa strains. Methods: A total of 114 carbapenem-resistant P. aeruginosa strains were isolated from different types of clinical specimens. The tested antibiotics were evaluated using the antibiotic disk diffusion method. Additionally, C/TandC/A were tested using the gradient test method. The efficacy of phenylalanine-arginine-beta-naphthylamide (PA beta N) as efflux pump inhibitors was assessed to determine their ability to reduce meropenem minimum inhibitory concentrations. Polymerase chain reaction (PCR) assays were conducted to identify bla(IMP), bla(VIM), and bla(NDM-1). Results: Among114 strains of carbapenem-resistant P. aeruginosa, overall resistance rates for C/T and C/A were 10.7% and 8.8%, respectively. Efflux pump inhibitor-based antibiotic susceptibility testing indicated that 35.08% of strains showed resistance modulated by PA beta N. Among the strains, 27 (24.5%) were found to produce metallo-beta-lactamase (MBL), with bla(VIM) (17 strains, 14.91%) being the most common, followed by bla(IMP) (12 strains, 10.53%). Conclusions: Emerging carbapenem resistance in P. aeruginosa strains is a serious therapeutic challenge for clinicians. Carbapenem resistance can be influenced by various factors, some of which were not assessed in our study. Nonetheless, our results revealed that themainmechanismassociated with carbapenem-resistant P. aeruginosa strains is a PA beta N-sensitiveeffluxpump. Among acquired MBLs, VIM-type enzymes were found to be the most prevalent.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Activity of ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa
    Wi, Y. M.
    Greenwood-Quaintance, K. E.
    Ko, K. S.
    Kwon, K. T.
    Jung, S. -I.
    Kim, Y. -S.
    Kim, S. -W.
    Yeom, J. -S.
    Peck, K. R.
    Song, J. -H.
    Patel, R.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S124 - S125
  • [2] The activity of ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa
    Ito, Carmen Antonia Sanches
    Bail, Larissa
    Arend, Lavinia Nery Villa Stangler
    Nogueira, Keite da Silva
    Tuon, Felipe Francisco
    [J]. INFECTIOUS DISEASES, 2021, 53 (05) : 386 - 389
  • [3] The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
    Christian M. Gill
    Elif Aktaþ
    Wadha Alfouzan
    Lori Bourassa
    Adrian Brink
    Carey-Ann D. Burnham
    Rafael Canton
    Yehuda Carmeli
    Marco Falcone
    Carlos Kiffer
    Anna Marchese
    Octavio Martinez
    Spyros Pournaras
    Michael Satlin
    Harald Seifert
    Abrar K. Thabit
    Kenneth S. Thomson
    Maria Virginia Villegas
    David P. Nicolau
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2021, 40 : 2533 - 2541
  • [4] The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
    Gill, Christian M.
    Aktap, Elif
    Alfouzan, Wadha
    Bourassa, Lori
    Brink, Adrian
    Burnham, Carey-Ann D.
    Canton, Rafael
    Carmeli, Yehuda
    Falcone, Marco
    Kiffer, Carlos
    Marchese, Anna
    Martinez, Octavio
    Pournaras, Spyros
    Satlin, Michael
    Seifert, Harald
    Thabit, Abrar K.
    Thomson, Kenneth S.
    Villegas, Maria Virginia
    Nicolau, David P.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021, 40 (12) : 2533 - 2541
  • [5] Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa
    Shields, Ryan K.
    Clancy, Cornelius J.
    Pasculle, A. William
    Press, Ellen G.
    Haidar, Ghady
    Hao, Binghua
    Chen, Liang
    Kreiswirth, Barry N.
    Nguyen, M. Hong
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (02)
  • [6] Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye
    Buyukyanbolu, Ecem
    Genc, Leyla
    Cyr, Elizabeth A.
    Karakus, Mehmet
    Comert, Fusun
    Otlu, Baris
    Aktas, Elif
    Nicolau, David P.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (09) : 1787 - 1794
  • [7] IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES
    Hosbul, Tugrul
    Aydogan, Canset Nur
    Kaya, Sinem
    Bedir, Rhan
    Ozcan, Hande
    Gumral, Ramazan
    [J]. JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2022, 85 (03): : 355 - 361
  • [8] Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa
    Kakehi, Ayaka
    Hagiya, Hideharu
    Iio, Koji
    Fujimori, Takumi
    Okura, Mami
    Minabe, Hiroshi
    Yokoyama, Yukika
    Otsuka, Fumio
    Higashikage, Akihito
    [J]. NEW MICROBIOLOGICA, 2023, 46 (02): : 213 - 215
  • [9] Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms
    Wi, Yu Mi
    Greenwood-Quaintance, Kerryl E.
    Schuetz, Audrey N.
    Ko, Kwan Soo
    Peck, Kyong Ran
    Song, Jae-Hoon
    Patel, Robin
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (01)
  • [10] Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
    Sekowska, Alicja
    Grabowska, Marta
    Bogiel, Tomasz
    [J]. MEDICINA-LITHUANIA, 2023, 59 (03):